CF
PTCT icon

Corebridge Financial’s PTC Therapeutics PTCT Stock Holding History

Corebridge Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,312
Closed -$1.9M – 2110
2025
Q1 		$1.9M Sell
37,312
-552
-1% -$27.5K 0.01% 999
2024
Q4 		$1.71M Sell
37,864
-2,859
-7% -$122K 0.01% 1082
2024
Q3 		$1.51M Sell
40,723
-251
-0.6% -$8.4K 0.01% 1168
2024
Q2 		$1.25M Buy
+40,974
New +$1.33M 0.01% 1224

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corebridge Financial's PTCT Position: Q2 2025 in Review

Corebridge Financial sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 37,312 shares — an estimated $1.9M sold.

Corebridge Financial first reported a position in PTCT in Q2 2024 and held it in 4 quarters. The position peaked at $1.9M in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Corebridge Financial reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 37,312 PTC Therapeutics shares in Q2 2025, an estimated $1.9M.
  • Corebridge Financial first reported a position in PTC Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's PTC Therapeutics position peaked at $1.9M in Q1 2025.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.